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Background: In Alzheimer’s disease, the extracellular deposition of
the -amyloid (A) peptide occurs due to aberrant processing of the
full-length A precursor protein (APP) by a group of proteases termed
secretase. Objective(s): Neurodegeneration is believed to be triggered
by the accumulation of potentially toxic A species which are gener-
ated following - and - secretase cleavage of APP. We have reported
earlier that memantine reduces the levels of the secreted APP (sAPP),
and A peptides in the human neuroblastoma (SK-N-SH) cells and in
rat primary cortical neurons. Methods: To understand the mechanism
of A reduction by memantine, the activity of - and -secretase
enzymes was determined in SK-N-SH cells treated with memantine (4
g/ ml for four days) using a fluorescent-based enzyme assay utilizing
enzyme-specific substrates and reporter molecules. For the -secretase
assay, the APP peptide substrate YEVHHQKLV and EDANS/DABCYL
as the reporter system were used. This substrate corresponds to the
amino acid sequence associated with -secretase cleavage of APP
(681-689). For the -secretase assay, the APP peptide substrate
REEVNLDAEFKR corresponding to the amino acid sequence with
-secretase cleavage of APP (668-675) was used. We also determined
the effects of memantine on the levels of soluble APP and A peptides
in the conditioned media by Western immunoblotting and ELISA as-
says. Results: Our MTT results indicate that there was no cellular loss
in memantine-treated cells compared to control, which was corrobo-
rated by LDH results showing no cellular toxicity. In our initial exper-
iments, memantine-treated cell extracts showed a reduction in - secre-
tase activity without any significant change in -secretase activity. The
levels of total sAPP, and A peptides were also reduced in memantine-
treated media compared to control. Conclusions: Further experiments
are in progress to better understand the mechanism of memantine’s
effect on secretases.
P4-311 PAN-811 PROTECTS PRIMARY NEURONS FROM
A NEUROTOXICITY: A POTENTIAL DRUG FOR
ALZHEIMER’S DISEASE
Hossein A. Ghanbari, Zhi-Gang Jiang, Panacea Pharmaceuticals, Inc.,
Gaithersburg, MD, USA. Contact e-mail: pstup@panaceapharma.com
Background: PAN-811 is a small lipophilic compound with a molecular
mass of 195 Dalton, belonging to the (N)-heterocyclic carboxaldehyde
thiosemicarbazone class of molecules originally developed for cancer ther-
apy. Our previous result has demonstrated highly effective function in
protecting ischemic neurotoxicity through a dual mechanism of divalent
metal chelation and free radical scavenging. It has proved to be non-toxic
in human clinical trials and crosses brain / blood barrier. Objective: We
have evidence that oxidative stress is the most likely mediator of A
neurotoxicity and our objective is to demonstrate that PAN-811 could be an
effective neuroprotector. Methods: To prove this hypothesis, first we
established that A has neurotoxicity in primary neurons in culture. Using
A1-42 or A25-35, the rate and intensity of neurotoxicity was increased
by age in culture and oxidative stress. For 2-week old neurons, the neu-
rotoxicity was observed in 12 to 16 days after the insult and required 0%
antioxidant level (high oxidative stress) whereas neurotoxicity occurred
after 1 day for 3-week old neurons under 90% antioxidant level(mild
oxidative stress). There was no neurotoxicity in young neurons low oxi-
dative stress when treated with less than 80m A. The neuronal cell death
was by apoptotic process. Neurotoxicty of A1-42 and A25-35 is specific
since a reversed sequence peptide A35-25 was unable to induce any
toxicity. Results: We have clearly demonstrated that PAN-811 inhibits
A-induced neurotoxity. PAN-811 at doses as low as 2M and as late as
3-hours post insult (A1-42 or A25-35 treatment) effectively protects
neurons. Conclusions: We conclude that PAN-811 protects primary neu-
rons from A neurotoxicity and should be pursued as a viable candidate for
therapeutic drug development for Alzheimer’s disease.
P4-312 A MODEL-BASED COMPARISON OF THE
NONCLINICAL AND CLINICAL EFFECTS OF
ANTI-A ANTIBODIES ON PLASMA A1-40
LEVELS
Eric R. Siemers, Lisa Ferguson-Sells, David G. Waters,
Ronald B. DeMattos, Ryan J. Hansen, Eli Lilly and Company,
Indianapolis, IN, USA. Contact e-mail: esiemers@lilly.com
Background: Administration of anti-A antibodies to animals and humans
produces increases in the total levels of A in the plasma. This biomarker
response provides evidence that the antibodies ‘hit the target’ and also
provides insight for comparison of effects between species. Objectives:
Although difficult to measure directly, an understanding of antibody effects
on ‘free’ A levels would also be advantageous, as one of the desired
effects of antibody administration is to decrease ‘free’ A levels and shift
A equilibria away from deposition into plaque. Methods: Mechanism-
based pharmacokinetic/pharmacodynamic (PK/PD) models were devel-
oped to characterize relationships between plasma anti-A antibody levels
and the time-course of the plasma A1-40 response in PDAPP mice and
Alzheimer’s patients. These models allow inference of effects on both
‘total’ and ‘free’ A. Simulations were performed to compare the relative
biomarker responses in PDAPP mice and humans. Results: Following
intraperitoneal administration of anti-A antibodies (m266) to PDAPP
mice, plasma m266 concentrations showed first-order absorption followed
by mono-exponential decay. In humans, intravenous anti-A antibody
administration led to bi-exponential pharmacokinetics that were well char-
acterized using a 2-compartment PK model. In both mice and humans,
antibody concentrations appeared to increase proportionally with admin-
istered dose. Dose-dependant plasma A1-40 pharmacodynamic responses
were observed in both mice and humans. These PD responses were well
characterized using mechanism-based PK/PD models that incorporated
antibody-antigen binding principles. Simulation results showed greater
effects on ‘free’ A1-40 at the dose levels administered in humans than for
the dose levels used for nonclinical efficacy studies in PDAPP mice.
Conclusions: This analysis illustrates that the dose levels studied in the
initial clinical study compare favorably, from a biomarker perspective,
with dose levels that demonstrated beneficial effects in PDAPP mice.
P4-313 ONLINE MEASUREMENT OF AMYLOID PLAQUE
DISSOLUTION IN TRANSGENIC MOUSE AND
HUMAN BRAIN TISSUE
Ivica Granic1, Botond Penke2, Gabor G. Kovacs3,
Ronald W.H. Verwer4, Olaf Selchow5, Eva Behrle5, Csaba Nyakas1,
Paul G.M. Luiten1, Ulrich L.M. Eisel1, 1University of Groningen,
Haren, The Netherlands; 2Albert Szent-Gyorgyi Medical University,
Szeged, Hungary; 3National Institute of Psychiatry and Neurology,
Budapest, Hungary; 4Netherlands Instiute for Brain Research,
Amsterdam, The Netherlands; 5University of Stuttgart, Stuttgart,
Germany. Contact e-mail: I.Granic@rug.nl
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by
a progressive loss of cognitive functions. The pathology of AD shows a
strong degeneration of neuritic processes, the presence of intracellular
neurofibrillary tangles and extracellular amyloid plaques.
According to the amyloid hypothesis the amyloid- peptide (A), which
accumulates in the brain of patients suffering from AD, is a major patho-
genic force in this disorder. Therefore, the reduction of amyloid deposits in
AD brain or inhibition of A fibrillogenesis is a promising target for
treating the disease.
As a result, a possible therapeutic approach can be the use of beta-sheet
breaker peptides. Beta-sheet breaker peptides are small synthetic peptides
(mainly penta-peptides) derived form the A sequences, which are able to
bind the amyloid- peptide and destabilize the beta-sheet-rich structure
therefore preventing aggregation and plaque formation.
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Here we established a novel method for testing amyloid resolving drugs on
brain slice cultures. Amyloid plaques in organotypic brain slice cultures
derived from either APPSL 
 PS1mut mice or tissue from AD patients
were stained using thioflavin S. A tissue incubation chamber was designed
for chronic treatment of amyloid plaques in living brain tissue with sheet
breaker peptides. The plaque dissolving properties of the sheet breakers
were measured up to 24 hours using confocal laser scanning microscopy.
Changes in plaque density were visualized after application of the beta-
sheet breaker peptides RVVIA, LPYFD and RIIGL in living tissue. After
incubation of 24 hours plaque reductions of up to 50% were established
dependent on sheet breaker composition and concentration. These results
indicate the promising potency of amyloid sheet breaker to combat plaque
density in ‘living’ brain tissue of AD patients. The experimental set up
using postmortem Alzheimer brain tissue provides a powerful tool for
measuring amyloid dissolving properties of newly developed anti-amyloid
compounds.
P4-314 OVEREXPRESSION OF NEPRILYSIN DECREASES
NEURONAL AND BEHAVIORAL IMPAIRMENTS
IN HUMAN AMYLOID PRECURSOR PROTEIN
TRANSGENIC MICE
William J. Meilandt, Tiffany Wu, Gui-Qiu Yu,
Kimberly Scearce-Levie, Lennart Mucke, Gladstone Institute of
Neurological Disease, San Francisco, CA, USA. Contact e-mail:
wmeilandt@gladstone.ucsf.edu
Background: Expression of human amyloid precursor proteins (hAPP)
and amyloid- (A) peptides in neurons of transgenic mice results in the
age-dependent development of neuritic plaques and of plaque-independent
synaptic and behavioral alterations. Several of the behavioral alterations
correlate with the depletion of synaptic activity-related proteins, such as
Fos and calbindin-28K, in the dentate gyrus, but not with plaque load.
Objective: Here we assessed whether neuronal and behavioral alterations
in hAPP mice are caused by A or by alternative hAPP metabolites such
as C-terminal fragments and secreted hAPP ectodomains. Methods: We
crossed hAPP mice from our familial Alzheimer’s disease-mutant line J20
with transgenic mice that overexpress the A-degrading enzyme neprilysin
in neurons [Neuron 40: 1087]. Neprilysin has previously been shown to
decrease the plaque burden in hAPP mice, but its effects on neuronal
deficits in hAPP mice remain to be defined. Results: Neprilysin (NEP)
overexpression reduced hippocampal A1-42 and A1-
 levels in hAPP/
NEP doubly transgenic mice compared with hAPP singly transgenic mice.
hAPP/NEP mice also had more Fos-positive granule cells and higher levels
of calbindin in the outer molecular layer of the dentate gyrus relative to
hAPP mice, although the levels of these proteins did not reach the levels in
the nontransgenic and NEP singly transgenic controls. Compared with
these controls, hAPP mice, but not hAPP/NEP mice, had increased hip-
pocampal levels of met-enkephalin. NEP overexpression also improved
several, but not all, behavioral alterations in hAPP mice. Conclusions:
These results suggest that neuronal and behavioral deficits in hAPP mice
are caused primarily by increased levels of A, underlining the therapeutic
potential of A-lowering strategies.
Supported by NIH grants AG022074 and NS43945.
P4-315 PHARMACODYNAMIC CHANGES IN PLASMA
A40 FOLLOWING PERIPHERAL ANTIBODY
TREATMENT IN TRANSGENIC MICE
Darrell A. Henze1, Stephanie Rosenberg1, Michelle C. Crouthamel1,
Sethu Sankaranarayanan1, Toni Williamson2, Pawel Richards2,
Mark S. Shearman2, Adam J. Simon1, Guy R. Seabrook1,
Gene G. Kinney1, 1Merck Research Laboraties, West Point, PA, USA;
2Merck Sharp and Dohme Research Laboratories, Harlow, United
Kingdom. Contact e-mail: darrell_henze@merck.com
Background: Antibodies against the Amyloid Beta (A) peptide oli-
gomers have been proposed as a therapeutic treatment for Alzheimer’s
disease. One mechanism by which these antibodies work is by binding and
sequestering A species in the periphery and thus reducing the amount of
A in the CNS. Transgenic PDAPP mice that strongly overexpress human
APP have been shown to demonstrate high plasma levels of A in the 24
hr period following a single acute IV dose of A specific antibody (De-
mattos et al 2001. PNAS 98:8850). Objective: To better understand the
relationship between A in the CNS and acute plasma elevations of
antibody-bound A40, we undertook a series of studies examining the
effects of different A monoclonal antibodies in two different transgenic
mouse lines (APP-YAC (2-5 mos) and Tg2576 (8-10 mos)) that express
human APP. Relative to WT controls, at baseline, the 2-4 mos APP-YAC
mouse has  3 fold elevations in brain DEA soluble A while the 8-10
mos Tg2576 mouse has  40 fold elevations in brain DEA soluble A.
Methods: Plasma elevations in A40 were measured using ELISA meth-
odology. Results: Using the A selective 4G8, WO2, or Merck mAb1
antibodies , we observed robust increases in plasma A40 in the 2-24 hr
period following a single IV injection of antibodies in both mouse strains.
The maximum elevation was observed between 4 and 12 hrs in the Tg 2576
and APP-YAC mice. The plasma elevations due to WO2 in Tg2576 were
dose dependent as were the elevations to Merck mAb1 in APP-YACS . The
A40 elevations were also observed with subcutaneous administration of
4G8 and Merck mAb1 although the magnitude of the response was slightly
smaller than the equivalent dose administered IV. Conclusions: Taken
together these data show that acute plasma elevations of A40 induced by
mAb administration can be observed in Tg AD mice and are a useful
pharmacodynamic marker of antibody activity.
P4-316 A DERIVATIVE VACCINE DOES NOT CAUSE
BRAIN MICROHEMORRHAGES IN TG2576 MICE
AND ITS EFFECTIVENESS IS AGE-DEPENDENT
Allal Boutajangout, Ayodeji A. Asuni, Henrieta Scholtzova,
Elin Knudsen, Yong-Sheng Li, David Quartermain, Blas Frangione,
Thomas Wisniewski, Einar M. Sigurdsson, NYU School of Medicine,
New York, NY, USA. Contact e-mail: boutaa01@med.nyu.edu
Background: Immunotherapy for AD targeting A remains promising
despite the setbacks in the initial clinical trial that may have been related
to T-cell-mediated encephalitis. Prior to these side effects, we advocated
that vaccination with A derivatives that are non-toxic and preferentially
elicit a Th2 immune response is likely to be safer for human use. In
addition, for enhanced safety, adjuvants that induce a humoral response,
such as alum, should be used. Another potential side effect of this type of
therapy is cerebral bleeding which has been observed following passive
immunization. This phenomenon has not been assessed in active immuni-
zation studies. Objective(s): To determine: 1) if our A derivatives are
effective when combined with alum; 2) whether our approach produces
hemorrhages; 3) whether the efficacy of our vaccine is age-dependent.
Methods: Tg2576 mice and wild-type littermates (n66) were immunized
with soluble, non-toxic A derivative, K6A1-30-NH2 in alum adjuvant,
starting at 11- and 19 months. This adjuvant is approved for humans and
promotes humoral immunity. Mice went through various sensorimotor and
cognitive tests at 22-24 months, and their brains were subsequently ana-
lyzed for amyloid burden and associated pathology including microhem-
orrhages. Results: Treatment initiated at 11 months reduced cortical plaque
burden by 31% (p0.05), total brain A40 levels by 30% (p0.03), A42
by 37% (p0.02), but soluble A levels remained unaltered. This effect
was associated with cognitive improvements in both the radial arm maze
and the Hebb-Williams maze. In contrast, treatment initiated at 19 months
was not immunogenic, did not reduce plaque burden or improve cognition.
In various sensorimotor tasks, Tg mice differed from their wild-type
littermates but treatment effect was not observed, indicating that the ther-
apy specifically improves cognition. Cerebral microhemorrhages were ob-
served in the Tg mice but the immunotherapy did not increase the bleeding
in contrast to previous A antibody studies. Conclusions: These findings
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